Could an arthritis drug stop a deadly skin condition?

NCT ID NCT07708038

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This trial tests whether tocilizumab, an anti-inflammatory drug, can stop the progression of calciphylaxis—a rare condition where calcium buildup blocks skin blood vessels, causing painful, non-healing wounds. Ten adults with calciphylaxis and end-stage kidney disease will receive three intravenous doses over 16 weeks. The study focuses on safety and whether the drug can reduce wound size and inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tocilizumab, an anti-inflammatory drug that blocks interleukin-6 (IL-6)
What this could lead to
If it works, this could point toward the first FDA-approved treatment for calciphylaxis, a rare and often fatal condition with no approved therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 10 participants, so results may not apply broadly. The drug also carries risks of serious infections and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CALCIPHYLAXIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Boston Medical Center

    Boston, Massachusetts, 02118, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.